These results led to the accelerated approval of erdafitinib by the FDA in April 2019 for previously treated FGFR3-altered urothelial carcinomas.10 Additional pan-FGFR inhibitors that have been studied in urothelial cancer include infigratinib (QED Therapeutics), pemigatinib (Incyte Corporation) and rogaratinib (Bayer). Here, FGFR3 is linked to urothelial carcinoma.